Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's (LLY.N), opens new tab weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 36.24% higher than today’s price of $756.00.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity star Zepbound. With the FDA’s green light on Friday, Lilly’s dual ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...

Earnings Report 1.900 USD Q4 2021 Earnings Release 02/03/2022 Indices Commodities Currencies Stocks ...

In a new head-to-head trial, drugmaker Eli Lilly said Wednesday that patients ... is the only obesity medicine proven to reduce the risk of cardiovascular (CV) death, stroke and heart attack ...

Congratulations to Prof Lily Kahn and Dr Riitta-Liisa Valijärvi on publishing "Baghdadi Judeo-Arabic," the first in the Textbooks of World and Minority Languages series, with the Oxford School of Rare ...

Wicked' star Ethan Slater filed for divorce from his wife of five years, Lilly Jay, shortly after his romance with Ariana Grande went public Theo Wargo/Getty Before his relationship with Ariana ...